Strategy

We seek to develop value-creating corporate alliances with commercial and academic partners. These alliances will be based on cutting-edge science, innovation and complementary attributes and skill sets. We will explore alliances in the areas of product discovery, development, manufacturing and commercialization in specific geographic regions world-wide.

Corporate Alliances: Product Development and Licensing Agreement

Green Cross Corp.
We currently have a product development and licensing agreement for JX-594 with Green Cross (Seoul, S. Korea) for the Korean market. Together we are focused on the development and eventual commercialization of JX-594 for liver cancers and other cancer indications in the Korean market. Green Cross is a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products.

Corporate Alliances: Research Collaborations

• Biogen Idec
  We currently have a research agreement in place with Biogen Idec (Cambridge, MA; San Diego, CA), a world-leader in cancer biotherapeutics research and development.

• Hybrid Systems
  We currently have a research agreement in place with Hybrid Systems (Oxford, UK), a company focused on viral coating technologies and IV virus delivery to cancers.

Academic Alliances: Clinical and Discovery Research Collaborations

• National Cancer Institute (Cell screening group)

• National Cancer Institute of Canada (Clinical Trials Group)

• University of Pittsburgh (David Bartlett, Chief of Surgery, Oncology)

• Institute of Cancer Research/Royal Marsden Hospital (London, UK)

• Oxford University (Dept. Clinical Pharmacology)